Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,842 across all filing types
Latest filing 2022-04-11 Annual Report
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
2021年年度报告摘要
Annual Report Classification · 95% confidence The document is titled as the "2021 Annual Report Summary" of 健帆生物科技集团股份有限公司, indicating it is a summary of the full annual report. It contains detailed financial data for the year 2021, including revenue, net profit, assets, and quarterly breakdowns. It also includes extensive business descriptions, product information, market position, and strategic initiatives. The document references the audit opinion and changes in accounting policies, which are typical components of an annual report. The length is substantial (15,000 characters), and it contains actual financial statements and substantive analysis, not just an announcement or a certification. Therefore, this document fits the definition of an Annual Report (10-K). FY 2021
2022-04-11 Chinese
中航证券有限公司关于公司2022年度日常关联交易预计的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from the sponsor (中航证券有限公司) regarding the 2022 annual expected ordinary related party transactions of 健帆生物科技集团股份有限公司. It includes descriptions of related party transactions, amounts, related parties, independent directors' opinions, and the sponsor's verification opinion. The document references regulatory rules related to securities issuance and listing, and it is focused on the expected related party transactions for the year 2022. It is not a full annual report or audit report, nor is it a brief announcement or a certification letter. The document is a formal verification opinion related to the sponsor's review of expected related party transactions, which is a type of audit or verification report related to compliance and internal controls but not a full audit report of financial statements. Therefore, the best fitting category is Audit Report / Information (AR). FY 2022
2022-04-11 Chinese
致同会计师事务所（特殊普通合伙）关于公司非经营性资金占用及其他关联资金往来的专项说明
Audit Report / Information Classification · 95% confidence The document is a special explanatory statement regarding non-operating fund occupation and other related party fund transactions for the year 2021 by 健帆生物科技集团股份有限公司. It includes a detailed summary table of these transactions and is addressed to an accounting firm. The document references an audit report issued by the accounting firm for the 2021 financial statements and states that the summary table should be read together with the audited financial statements. The document is signed by the accounting firm and company representatives and is intended for disclosure in the annual report. The document length is 2944 characters, which is relatively short and focused on a specific audit-related explanation rather than a full annual report or standalone audit report. It is not a full Annual Report (10-K) or Interim Report (IR), nor is it a general regulatory filing or announcement. It is a specialized audit-related explanatory statement about related party transactions and non-operating fund occupation, which fits best under Audit Report / Information (AR) as it supplements the audit findings and provides detailed audit-related disclosures without being the full annual report itself. FY 2021
2022-04-11 Chinese
2021年度内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Internal Control Self-Evaluation Report" for the year 2021 by 健帆生物科技集团股份有限公司. It discusses the company's internal control systems, evaluation of internal control effectiveness, control environment, control procedures, and related governance and audit functions. The document is detailed and contains substantive content about internal control evaluation, including standards, scope, and conclusions. It is not an announcement or a brief summary but a full report on internal control self-assessment. This type of document aligns with an Audit Report / Information (AR) category, as it focuses on internal control evaluation and audit-related information rather than a full annual report or financial statements. Therefore, the appropriate classification is AR with high confidence. FY 2021
2022-04-11 Chinese
关于2021年年度报告披露的提示性公告
Report Publication Announcement Classification · 100% confidence The document is a short announcement (467 characters) from a company about the disclosure of its 2021 Annual Report. It states that the full annual report and summary will be disclosed on a specific date on a regulatory website. There is no actual financial data or report content included, only a notice about the report's availability. According to the 'MENU VS MEAL' rule, such a short document announcing the publication of a report should be classified as a Report Publication Announcement (RPA), not as the Annual Report (10-K) itself.
2022-04-11 Chinese
2021年年度财务报告
Annual Report Classification · 95% confidence The document is titled as the 2021年度财务决算报告 (2021 Annual Financial Settlement Report) of 健帆生物科技集团股份有限公司. It contains detailed financial data including income, profit, assets, liabilities, cash flow, and financial ratios for the year 2021 compared to 2020. The length is 8454 characters, which is substantial and contains actual financial statements and analysis. The content is comprehensive and covers the full fiscal year financial performance, which aligns with the definition of an Annual Report (10-K). There is no indication that this is merely an announcement or a certification, and it is not a quarterly or interim report since it covers the full year. Therefore, the document should be classified as an Annual Report (10-K). FY 2021
2022-04-11 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.